Jacek Rutkowski1, Magdalena Szymanik1, Maciej Blok1, Joanna Kozaka2, Renata Zaucha1. 1. Medical University of Gdansk, Department of Clinical Oncology and Radiotherapy, ul. Dębinki 7, 80-952 Gdańsk, Poland. 2. University of Gdansk, Institute of Psychology, ul. Jana Bażyńskiego 4, 80-309 Gdańsk, Poland.
Abstract
AIM: The aim of this prospective study was to evaluate the level of anxiety, depression, and quality of life (QoL) in medically inoperable patients with early stage non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR). BACKGROUND: Prolonged survival is equally important as maintaining high QoL and good psychological functioning during the treatment of lung cancer. Nowadays available SABR has markedly changed clinical care and outcomes in the group of medically inoperable patients. To our knowledge, analysis of QoL and psychological state has not been performed in Polish patients with early NSCLC treated with SABR. MATERIALS AND METHODS: Research group consisted of medically inoperable, early NSCLC (T1-2aN0M0) patients qualified to SABR. Patients were asked to complete Polish versions of the European Organization for Research and Treatment of Cancer Quality of Life - Core Questionnaire (EORTC QLQ-C30) with the Lung Cancer Questionnaire (LC13) and Hospital Anxiety and Depression Scale (HAD). These questionnaires were repeated 2 weeks and then 3 months after treatment completion. RESULTS: We enrolled 51 patients who met the inclusion criteria. SABR did not deteriorate QoL and psychological functioning. On the contrary, clinically meaningful improvement was observed in emotional functioning, level of insomnia, anxiety and depression. Significantly worse improvement was shown in patients with chronic obstructive pulmonary disease (COPD). CONCLUSIONS: Our results confirm that SABR is well tolerated and does not have a deleterious effect on QoL and psychological state. Results of our study indicate the importance of additional psychological care in the group of patients with COPD.
AIM: The aim of this prospective study was to evaluate the level of anxiety, depression, and quality of life (QoL) in medically inoperable patients with early stage non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR). BACKGROUND: Prolonged survival is equally important as maintaining high QoL and good psychological functioning during the treatment of lung cancer. Nowadays available SABR has markedly changed clinical care and outcomes in the group of medically inoperable patients. To our knowledge, analysis of QoL and psychological state has not been performed in Polish patients with early NSCLC treated with SABR. MATERIALS AND METHODS: Research group consisted of medically inoperable, early NSCLC (T1-2aN0M0) patients qualified to SABR. Patients were asked to complete Polish versions of the European Organization for Research and Treatment of Cancer Quality of Life - Core Questionnaire (EORTC QLQ-C30) with the Lung Cancer Questionnaire (LC13) and Hospital Anxiety and Depression Scale (HAD). These questionnaires were repeated 2 weeks and then 3 months after treatment completion. RESULTS: We enrolled 51 patients who met the inclusion criteria. SABR did not deteriorate QoL and psychological functioning. On the contrary, clinically meaningful improvement was observed in emotional functioning, level of insomnia, anxiety and depression. Significantly worse improvement was shown in patients with chronic obstructive pulmonary disease (COPD). CONCLUSIONS: Our results confirm that SABR is well tolerated and does not have a deleterious effect on QoL and psychological state. Results of our study indicate the importance of additional psychological care in the group of patients with COPD.
Entities:
Keywords:
Anxiety and depression; NSCLC; Quality of life; SABR; Stereotactic radiotherapy
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Frank J Lagerwaard; Neil K Aaronson; Chad M Gundy; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan Journal: J Thorac Oncol Date: 2012-07 Impact factor: 15.609
Authors: John T Maringwa; Chantal Quinten; Madeleine King; Jolie Ringash; David Osoba; Corneel Coens; Francesca Martinelli; Jurgen Vercauteren; Charles S Cleeland; Henning Flechtner; Carolyn Gotay; Eva Greimel; Martin J Taphoorn; Bryce B Reeve; Joseph Schmucker-Von Koch; Joachim Weis; Egbert F Smit; Jan P van Meerbeeck; Andrew Bottomley Journal: Support Care Cancer Date: 2010-10-01 Impact factor: 3.603
Authors: Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; S Senan Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: Pepijn Brocken; Erik H F M van der Heijden; Karen T M Oud; Gerben Bootsma; Harry J M Groen; A Rogier T Donders; P N Richard Dekhuijzen; Judith B Prins Journal: Psychooncology Date: 2014-09-09 Impact factor: 3.894
Authors: Dan J Raz; Jason A Zell; S-H Ignatius Ou; David R Gandara; Hoda Anton-Culver; David M Jablons Journal: Chest Date: 2007-05-15 Impact factor: 9.410
Authors: M Guckenberger; N Andratschke; H Alheit; R Holy; C Moustakis; U Nestle; O Sauer Journal: Strahlenther Onkol Date: 2013-09-21 Impact factor: 3.621
Authors: Henry S Park; Frank C Detterbeck; David C Madoff; Brett C Bade; Ulas Kumbasar; Vincent J Mase; Andrew X Li; Justin D Blasberg; Gavitt A Woodard; Whitney S Brandt; Roy H Decker Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005